Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | FCGR1A | P12314 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.50 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.50 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.50 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL15579214 | 0.92 | NTRK1 (0.48) | NTRK1MAPK1CYP1A2CYP2C19GAA | |
| SCHEMBL28594276 | 0.89 | NTRK1 (0.56) | NTRK1MAPK1CYP1A2CYP2C19GAA | |
| SCHEMBL28594274 | 0.89 | NTRK1 (0.56) | NTRK1MAPK1CYP1A2CYP2C19GAA | |
| SCHEMBL20320311 | 0.84 | NTRK1 (0.56) | NTRK1MAPK1CYP1A2CYP2C19GAA | |
| SCHEMBL21774133 | 0.84 | MAPT (0.49) | NTRK1MAPK1CYP1A2CYP2C19GAA | |
| SCHEMBL499894 | 0.83 | NTRK1 (0.51) | NTRK1MAPK1CYP1A2CYP2C19GAA | |
| SCHEMBL20320310 | 0.83 | KMT2A (0.54) | NTRK1MAPK1CYP1A2CYP2C19GAA | |
| SCHEMBL314157 | 0.82 | MAPT (0.46) | MAPK1CYP2C19GAAKMT2ATSHR | |
| SCHEMBL28580354 | 0.82 | GAA (0.52) | NTRK1MAPK1CYP1A2CYP2C19GAA | |
| SCHEMBL21775684 | 0.82 | NTRK1 (0.47) | NTRK1MAPK1CYP1A2CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2025671-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, MPL, IL1RN | NTRK1 124/4885MAPK1 426/4885CYP1A2 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.